Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Injectable scopolamine augmentation for major depressive disorder
IRCT20231017059749N1Phase 3Completed
- Sponsor
- Arak University of Medical Sciences
- Start
- Oct 2023
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of scopolamine in major depressive disorder (MDD) (2 arms), sponsored by Arak University of Medical Sciences. Primary endpoint: Hamilton depression scale. Started Oct 2023; status: completed.
02
Drugs
scopolamine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on IRCT20231017059749N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20231017059749N1.